BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 30, Pages 8065-8070
Publisher
Proceedings of the National Academy of Sciences
Online
2017-07-12
DOI
10.1073/pnas.1704173114
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer
- (2016) Marina Cardó-Vila et al. AMERICAN JOURNAL OF PATHOLOGY
- Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
- (2016) E. Palmerini et al. BMC CANCER
- Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience
- (2016) Christopher Kuo et al. PEDIATRIC BLOOD & CANCER
- Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy
- (2016) Jun Ah Lee et al. PEDIATRIC BLOOD & CANCER
- Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study
- (2015) Renata Pasqualini et al. CANCER
- Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
- (2015) K. Karjalainen et al. CLINICAL CANCER RESEARCH
- Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
- (2015) Stefan S. Bielack et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients
- (2014) Akmal Safwat et al. ACTA ONCOLOGICA
- Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
- (2014) Lars M. Wagner et al. PEDIATRIC BLOOD & CANCER
- Interleukin-11 receptor α is overexpressed in human osteosarcoma, and near-infrared-labeled IL-11Rα imaging agent could detect osteosarcoma in mouse tumor xenografts
- (2014) Tao Liu et al. TUMOR BIOLOGY
- Fiji: an open-source platform for biological-image analysis
- (2012) Johannes Schindelin et al. NATURE METHODS
- Genetically Modified T cells Targeting Interleukin-11 Receptor -Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases
- (2011) G. Huang et al. CANCER RESEARCH
- The Interleukin-11 Receptor as a Candidate Ligand-Directed Target in Osteosarcoma: Consistent Data from Cell Lines, Orthotopic Models, and Human Tumor Samples
- (2009) V. O. Lewis et al. CANCER RESEARCH
- Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma
- (2008) Fariba Navid et al. CANCER
- Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
- (2008) Paul A. Meyers et al. JOURNAL OF CLINICAL ONCOLOGY
- Technical pitfalls potentially affecting diagnoses in immunohistochemistry
- (2008) G Bussolati et al. JOURNAL OF CLINICAL PATHOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now